Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunitinib + pemetrexed
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sunitinib + pemetrexed is a combination therapy that has been investigated for the treatment of advanced solid malignancies. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that blocks cellular signaling by targeting multiple RTKs including PDGF-R, VEGF-R, KIT (CD117), RET, CSF-1R, and flt3. Pemetrexed is a folate analog chemotherapy drug that works by blocking the action of certain substances in the body that may help cancer cells multiply. The combination has been studied in clinical trials, particularly in patients with non-small cell lung cancer (NSCLC) and mesothelioma.
- Brand names
- SutentAlimta
- Other names
- sunitinib malatepemetrexed disodium
02
Targets
DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)GART (GAR transformylase)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on sunitinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunitinib + pemetrexed.